Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 140

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 140
---
 calculate financial results as presented under IFRS for the previous fiscal year, this does not necessarily mean that the transactions entered into during the relevant fiscal year could have been entered into or would have been recorded at the same exchange rates. Moreover, other companies in our industry using similarly titled measures may define and calculate those measures differently than we do and therefore such measures may not be directly comparable. Accordingly, CER change should not be considered in isolation and is not, and should not be viewed as, a substitute for change in financial results as prepared and presented in accordance with IFRS.

Table of Contents

The following tables show our results of operations, including the year-over-year percentages changes thereto, in each case as calculated and presented in accordance with IFRS, and reconcile the CER percentage changes for each line item to such presentation.

CER Change (Reported Measures):

                                                                                        Billion JPY or percentage                                                                                      
                                                                                        For the fiscal year ended                                                     AER                         CER  
                                                                                                        March 31,                                                  (IFRS)                  (Non-IFRS)  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                                                                                       ¥        4,263.8            ¥        4,581.6            ¥         7.5             2.9  
  Cost of sales                                                                                                        (1,426.7)                   (1,580.2)      (153.5)        10.8             6.5  
  Selling, general and administrative expenses                                                                         (1,053.8)                   (1,104.8)       (50.9)         4.8             0.6  
  Research and development expenses                                                                       (729.9)                     (730.2)                       (0.3)         0.0           (4.5)  
  Amortization and impairment losses on intangible assets associated with products                        (652.1)                     (643.2)                         8.9       (1.4)           (6.0)  
  Other operating income                                                                                     19.4                        26.2                         6.8        35.3            30.8  
  Other operating expenses                                                                                (206.5)                     (206.7)                       (0.2)         0.1           (3.6)  
  Operating profit                                                                                          214.1